Why MedTech’s Most Critical Leadership Gap Is Getting Harder to Ignore
Engineering expertise and regulatory accountability almost never sit in the same person. As of February 2, 2026, FDA’s new inspection framework follows risk across the full product lifecycle—and that gap is no longer a background risk. It is a current exposure.
Proton Therapy as a Case Study in Systems IntegrationEngineering, Regulatory, and Operations at the Frontier
A particle accelerator. A 100-ton rotating gantry. 20 major assemblies from across the globe. 50+ international safety standards as design inputs. One FDA 510(k) submission. This is what real systems integration complexity looks like—and what it teaches about every program that follows.
Transforming Healthcare Through Strategic AI Integration: A Partnership Approach to Medical Device and Life Sciences Innovation
87% of healthcare AI initiatives stall before production. 95% never deliver ROI. The root cause isn’t the technology—it’s fragmented accountability. When strategy, development, and deployment are owned by separate vendors, the client becomes the de facto systems integrator.
The Game Has Changed: Why FDA’s New Risk-Based Inspection Process Demands a Different Kind of Consultant
February 2, 2026: FDA’s new inspection manual made checklist inspections obsolete overnight. Now investigators follow risk through interconnected processes—and if your QMS can’t demonstrate bidirectional traceability in real-time, you’re not ready.
Unlocking $36 Billion in Value: Transform Your Medical Device Regulatory Processes into a Competitive Advantage
47% of medical device leaders name compliance their #1 priority — yet it consumes $26–$36B annually. With FDA QMSR effective February 2, 2026, the window to act is now. Here’s how to turn regulatory excellence into competitive advantage.